skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Differences in biodistribution of indium-111-and iodine-131-labeled B72. 3 monoclonal antibodies in patients with colorectal cancer

Journal Article · · J. Nucl. Med.; (United States)
OSTI ID:5601984

We have compared the biodistributions of (/sup 131/I)B72.3 and /sup 111/In-SCN-Bz-DTPA B72.3 monoclonal antibody (MoAb) in patients with metastatic colon cancers. B72.3 is an IgG1 that recognizes a mucin-like colon cancer associated antigen. Eight patients were infused with 3-5 mCi and 0.36-20 mg of /sup 111/In-labeled B72.3 prepared with a bifunctional chelate, isothiocyanatobenzyl-DTPA (SCN-Bz-DTPA). The biodistribution was compared with that of 13 patients previously studied as part of a separate trial, with 1-10 mCi and 0.16-1.35 mg of (/sup 131/I)B72.3. The Beta T1/2 in serum was 63 +/- 5 hr for 111In-SCN-Bz-DTPA B72.3 and 52 +/- 10 hr for (/sup 131/I)B72.3. Whole-body retention of the /sup 111/In (T1/2 = 11.8 days) was significantly longer than for (/sup 131/I)B72.3 (T1/2 = 3.3 days), p less than 0.000001. The /sup 131/I was excreted primarily through the urine. Urinary excretion of /sup 111/In was low and gamma camera images confirmed that some /sup 111/In was excreted in the bowel. Tumor localization was seen in one of seven evaluable patients receiving /sup 111/In-SCN-Bz-DTPA B72.3. Gamma camera images showed that the liver concentrates /sup 111/In but not /sup 131/I. We conclude that /sup 111/In-SCN-Bz-DTPA B72.3 is metabolized in a different manner from the iodinated B72.3. The high concentration and prolonged retention of /sup 111/In by the liver interferes with tumor imaging of metastases.

Research Organization:
Warren G. Magnuson Clinical Center, Bethesda, MD (USA)
OSTI ID:
5601984
Journal Information:
J. Nucl. Med.; (United States), Vol. 30:3
Country of Publication:
United States
Language:
English